Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Academic Press Country of Publication: United States NLM ID: 100883537 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-7035 (Electronic) Linking ISSN: 15216616 NLM ISO Abbreviation: Clin Immunol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Orlando, FL : Academic Press, c1999-
    • Subject Terms:
      AIDS Vaccines* ; COVID-19* ; Influenza Vaccines* ; Papillomavirus Vaccines* ; Respiratory Syncytial Virus Vaccines* ; SAIDS Vaccines*; Antibodies, Neutralizing ; Antibodies, Viral ; BCG Vaccine ; COVID-19 Vaccines ; Diphtheria-Tetanus-Pertussis Vaccine ; Humans ; Measles-Mumps-Rubella Vaccine ; SARS-CoV-2 ; Survivors
    • Abstract:
      The severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) survivors are more likely to produce a potent immune response to SARS-CoV-2 after booster vaccination. We assessed humoral and T cell responses against SARS-CoV-2 in previously vaccinated SARS-CoV-1 survivors and naïve healthy individuals (NHIs) after a booster Ad5-nCoV dose. Boosted SARS-CoV-1 survivors had a high neutralization of SARS-CoV-2 Wuhan-Hu-1 (WA1), Beta, and Delta but is limited to Omicron subvariants (BA.1, BA.2, BA.2.12.1, and BA.4/BA.5). Most boosted SARS-CoV-1 survivors had robust SARS-CoV-2-specific CD4 + and CD8 + T cell responses. While booster vaccination in NHIs elicited less or ineffective neutralization of WA1, Beta, and Delta, and none of them induced neutralizing antibodies against Omicron subvariants. However, they developed comparable SARS-CoV-2-specific T cell responses compared to boosted SARS-CoV-1 survivors. These findings suggest that boosted Ad5-nCoV would not elicit effective neutralizing antibodies against Omicron subvariants in SARS-CoV-1 survivors and NHIs but induced comparable robust T cell responses. Achieving a high antibody titer in SARS-CoV-1 survivors and NHIs is desirable to generate broad neutralization.
      Competing Interests: Declaration of Competing Interest We declare no competing interests.
      (Copyright © 2022 Elsevier Inc. All rights reserved.)
    • References:
      Nature. 2022 Feb;602(7898):664-670. (PMID: 35016195)
      Nature. 2022 Mar;603(7902):679-686. (PMID: 35042229)
      N Engl J Med. 2022 Apr 21;386(16):1532-1546. (PMID: 35249272)
      N Engl J Med. 2022 Mar 17;386(11):1088-1091. (PMID: 35081298)
      Hum Immunol. 2004 May;65(5):523-36. (PMID: 15172453)
      Nature. 2021 Feb;590(7847):630-634. (PMID: 33276369)
      Cell. 2022 Mar 3;185(5):847-859.e11. (PMID: 35139340)
      Science. 2020 Oct 2;370(6512):89-94. (PMID: 32753554)
      N Engl J Med. 2022 May 12;386(19):1804-1816. (PMID: 35263534)
      Nature. 2022 Feb;602(7898):676-681. (PMID: 35016198)
      Science. 2021 Mar 25;:. (PMID: 33766944)
      Nat Med. 2022 Mar;28(3):472-476. (PMID: 35042228)
      Nat Commun. 2022 Mar 28;13(1):1614. (PMID: 35347129)
      Cell Host Microbe. 2022 Aug 10;30(8):1093-1102.e3. (PMID: 35526534)
      Nature. 2020 Aug;584(7821):457-462. (PMID: 32668444)
      Nat Med. 2022 Mar;28(3):477-480. (PMID: 35046572)
      Nat Microbiol. 2021 Nov;6(11):1433-1442. (PMID: 34654917)
      Cell. 2022 Feb 3;185(3):447-456.e11. (PMID: 35026151)
      Cell. 2020 Jun 25;181(7):1489-1501.e15. (PMID: 32473127)
      Immunity. 2020 Aug 18;53(2):248-263. (PMID: 32717182)
      Lancet Infect Dis. 2022 Jun;22(6):766-767. (PMID: 35427493)
      Nature. 2022 Feb;602(7898):671-675. (PMID: 35016199)
      Cell Rep Med. 2021 Jul 20;2(7):100354. (PMID: 34250512)
      Science. 2021 Feb 19;371(6531):759. (PMID: 33602830)
      Viruses. 2020 Feb 25;12(3):. (PMID: 32106567)
      Sci Immunol. 2022 Mar 25;7(69):eabo2202. (PMID: 35113647)
      N Engl J Med. 2021 Dec 9;385(24):e84. (PMID: 34614326)
      Nature. 2021 Aug;596(7870):109-113. (PMID: 34182569)
      Nature. 2020 Nov;587(7833):270-274. (PMID: 32726801)
      N Engl J Med. 2021 Jun 10;384(23):2259-2261. (PMID: 33822494)
      Signal Transduct Target Ther. 2021 Sep 27;6(1):349. (PMID: 34580279)
      Science. 2021 Feb 5;371(6529):. (PMID: 33408181)
      Cell Host Microbe. 2022 Aug 10;30(8):1103-1111.e6. (PMID: 35588741)
      Nature. 2022 Mar;603(7901):488-492. (PMID: 35102311)
      Sci Transl Med. 2021 Jun 30;13(600):. (PMID: 34103407)
      Nature. 2022 Mar;603(7901):493-496. (PMID: 35102312)
      N Engl J Med. 2021 Oct 7;385(15):1401-1406. (PMID: 34407341)
      Cell. 2022 Feb 3;185(3):457-466.e4. (PMID: 34995482)
      Emerg Microbes Infect. 2020 Dec;9(1):680-686. (PMID: 32207377)
      Bioinformatics. 2021 Dec 25;:. (PMID: 34954792)
      mBio. 2022 Apr 26;13(2):e0297921. (PMID: 35352979)
      Nat Protoc. 2020 Nov;15(11):3699-3715. (PMID: 32978602)
      Nature. 2022 Feb;602(7895):148-155. (PMID: 34875673)
    • Contributed Indexing:
      Keywords: Booster vaccination; Omicron; SARS-CoV-1 survivors; SARS-CoV-2; T-cell response
    • Accession Number:
      0 (AIDS Vaccines)
      0 (Antibodies, Neutralizing)
      0 (Antibodies, Viral)
      0 (BCG Vaccine)
      0 (COVID-19 Vaccines)
      0 (Diphtheria-Tetanus-Pertussis Vaccine)
      0 (Influenza Vaccines)
      0 (Measles-Mumps-Rubella Vaccine)
      0 (Papillomavirus Vaccines)
      0 (Respiratory Syncytial Virus Vaccines)
      0 (SAIDS Vaccines)
    • Publication Date:
      Date Created: 20220901 Date Completed: 20221012 Latest Revision: 20221222
    • Publication Date:
      20231215
    • Accession Number:
      PMC9423872
    • Accession Number:
      10.1016/j.clim.2022.109103
    • Accession Number:
      36049602